The Impact of the COVID-19 Pandemic on Exacerbations and Symptoms in Bronchiectasis: A Prospective Study

Megan L. Crichton; Amelia Shoemark; James D. Chalmers

doi:10.1164/rccm.202105-1137LE

The Impact of the COVID-19 Pandemic on Exacerbations and Symptoms in Bronchiectasis: A Prospective Study

Megan L. Crichton, Amelia Shoemark, James D. Chalmers (Lead / Corresponding author)

Research output: Contribution to journal › Letter › peer-review

40 Citations (Scopus)

106 Downloads (Pure)

Original language	English
Pages (from-to)	857-859
Number of pages	3
Journal	American Journal of Respiratory and Critical Care Medicine
Volume	204
Issue number	7
Early online date	15 Jul 2021
DOIs	https://doi.org/10.1164/rccm.202105-1137LE
Publication status	Published - 1 Oct 2021

Keywords

Bronchiectasis
COVID-19
Exacerbations
Symptoms

ASJC Scopus subject areas

Critical Care and Intensive Care Medicine
Pulmonary and Respiratory Medicine

Access to Document

10.1164/rccm.202105-1137LELicence: CC BY-NC-ND

Final published versionFinal published version, 573 KBLicence: CC BY-NC-ND

Cite this

@article{9287bad989ba497994d4c763a4e544ca,

title = "The Impact of the COVID-19 Pandemic on Exacerbations and Symptoms in Bronchiectasis: A Prospective Study",

keywords = "Bronchiectasis, COVID-19, Exacerbations, Symptoms",

author = "Crichton, {Megan L.} and Amelia Shoemark and Chalmers, {James D.}",

note = "This work was supported by the Innovative Medicines Initiative (IMI) and EFPIA companies under the European Commission funded project, and iABC (grant 115721), the European Respiratory Society through the EMBARC2 consortium and the United States BRR / COPD Foundation. EMBARC2 is supported by project partners Astrazeneca, Chiesi, Grifols, Janssen, Insmed, Novartis and Zambon. JDC is supported by the GSK/British Lung Foundation Chair of Respiratory Research.",

year = "2021",

month = oct,

day = "1",

doi = "10.1164/rccm.202105-1137LE",

language = "English",

volume = "204",

pages = "857--859",

journal = "American Journal of Respiratory and Critical Care Medicine",

issn = "1073-449X",

publisher = "American Thoracic Society",

number = "7",

}

TY - JOUR

T1 - The Impact of the COVID-19 Pandemic on Exacerbations and Symptoms in Bronchiectasis

T2 - A Prospective Study

AU - Crichton, Megan L.

AU - Shoemark, Amelia

AU - Chalmers, James D.

N1 - This work was supported by the Innovative Medicines Initiative (IMI) and EFPIA companies under the European Commission funded project, and iABC (grant 115721), the European Respiratory Society through the EMBARC2 consortium and the United States BRR / COPD Foundation. EMBARC2 is supported by project partners Astrazeneca, Chiesi, Grifols, Janssen, Insmed, Novartis and Zambon. JDC is supported by the GSK/British Lung Foundation Chair of Respiratory Research.

PY - 2021/10/1

Y1 - 2021/10/1

KW - Bronchiectasis

KW - COVID-19

KW - Exacerbations

KW - Symptoms

UR - http://www.scopus.com/inward/record.url?scp=85116535837&partnerID=8YFLogxK

U2 - 10.1164/rccm.202105-1137LE

DO - 10.1164/rccm.202105-1137LE

M3 - Letter

C2 - 34265234

SN - 1073-449X

VL - 204

SP - 857

EP - 859

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

IS - 7

ER -

The Impact of the COVID-19 Pandemic on Exacerbations and Symptoms in Bronchiectasis: A Prospective Study

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis (iABC) (Joint with 19 Partners)

Cite this

The Impact of the COVID-19 Pandemic on Exacerbations and Symptoms in Bronchiectasis: A Prospective Study

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Projects

Inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis (iABC) (Joint with 19 Partners)

Cite this